In a landmark development for India's healthcare sector, Lord's Mark Industries Limited has become the first and only company in the country to receive a manufacturing license for an In Vitro Diagnostic Software (Software as a Medical Device – SaMD) for its Biomescan Analytics Platform. According to reports from Business Standard, this milestone positions the company at the forefront of an emerging preventive healthcare opportunity, bringing gut microbiome science closer to mainstream wellness and early health management. The development comes as India's preventive healthcare ecosystem gains momentum, with innovations like Biomescan designed to enable early intervention before symptoms appear, transforming healthcare from reactive treatment to proactive prevention.
The licensing comes at an opportune time as India's gut health market enters a high-growth phase, valued at USD 565.51 million in 2025 and projected to reach USD 1,619.56 million by 2034, expanding at a CAGR of 11.07%. As reported by Business Standard, with the market expected to grow substantially over the next three years, the license positions Lord's Mark Industries Limited strategically for this expanding market opportunity. The platform addresses a critical need as non-communicable diseases account for a growing share of India's healthcare burden, making innovations that enable early risk identification and personalized preventive care crucial for improving health outcomes. Scientific research increasingly links the gut microbiome with lifestyle disorders such as diabetes, obesity, cardiovascular diseases, digestive disorders and weakened immunity, creating significant market demand for preventive solutions.
The Biomescan Analytics Platform combines whole metagenome sequencing data with a validated bioinformatics pipeline to generate detailed gut microbiome profiles, diversity scores, enterotype classification, functional metabolic assessments and personalized nutritional recommendations. According to Business Standard, the platform provides comprehensive insights into microbial diversity, metabolic functions, disease susceptibility indicators and evidence-based personalized dietary recommendations. The platform is particularly valuable for fertility issues, which represents a significant focus area for Lord's Mark Industries to benefit people and gather market share in this sector. By analysing an individual's gut microbiome through advanced bioinformatics, Biomescan provides insights that can help reduce the risk of future health complications and improve long-term wellness. Unlike conventional healthcare that often begins after symptoms appear, Biomescan is designed to encourage early intervention, enabling healthcare professionals to recommend personalized nutrition and lifestyle modifications that may help reduce the risk of future health complications and improve long-term wellness.
Building on this innovation, Lord's Mark Industries plans to establish a nationwide network of Health & Wellness Centres in collaboration with hospitals, doctors and healthcare institutions. As reported by Business Standard, these centres will enable individuals to undergo gut microbiome assessments, receive scientifically backed nutritional guidance and adopt preventive healthcare strategies tailored to their unique biological profile. The company aims to establish 3,000 centres across India within the next three years and plans to launch app-based services soon. Post this test result, LMIL would be able to ascertain the right diet for patients and right protein formulation so that individual beneficiaries of test results can lead healthy lifestyles and stay fit. Through partnerships with hospitals and medical professionals across India, the company aims to make preventive healthcare accessible, affordable and impactful for millions.
Commenting on the development, Sachidanand Upadhyay, Managing Director of Lord's Mark Industries Ltd., stated that healthcare is moving from reactive treatment to proactive prevention. According to Business Standard, the company's vision is to empower every individual with scientific insights into their own health before disease develops, representing a new era where genomics and nutrition come together to create truly personalized wellness. The platform is licensed as a wellness and health-information tool and is not intended for standalone clinical diagnosis or therapeutic decision-making. Through Biomescan, Lord's Mark Industries aims to position India at the forefront of microbiome-driven preventive healthcare while creating a scalable wellness ecosystem for the future. With the platform combining whole metagenome sequencing data with validated bioinformatics, Biomescan makes it one of India's most advanced microbiome wellness platforms, designed to transform preventive healthcare through personalized nutrition, early health risk assessment, and nationwide wellness centres.
